The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The role of epcoritamab in third-line or later LBCL
Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the emerging role of bispecific antibodies in the treatment of third-line or later large B-cell lymphoma (LBCL), particularly focusing on epcoritamab. Dr Cheah highlights the promising safety and efficacy data for epcoritamab, even in patients who have been exposed to CAR-T therapy, and further comments on the manageable side effect profile of this agent. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
